share_log

Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $120

Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $120

大摩资源lof维持在德康医疗股票上的等权重评级,将目标价格下调至120美元。
Benzinga ·  07/15 12:50

Morgan Stanley analyst Patrick Wood maintains DexCom (NASDAQ:DXCM) with a Equal-Weight and lowers the price target from $132 to $120.

大摩资源lof的分析师Patrick Wood维持德康医疗(纳斯达克股票代码:DXCM)的等权重评级,并将价格目标从132美金下调至120美金。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发